Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Clinical Trials in Cleveland, Ohio

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer